部分遗传性皮肤病的治疗进展

doi:10.35541/cjd.20220001

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (8): 735-739.doi: 10.35541/cjd.20220001

部分遗传性皮肤病的治疗进展

晋亮¹ 刘玲²

¹解放军空军特色医学中心，北京 100142；²第四军医大学西京皮肤医院，西安 710032

收稿日期:2022-01-04 修回日期:2022-02-25 发布日期:2022-08-02
通讯作者: 刘玲 E-mail:vanilla@fmmu.edu.cn
基金资助:
空军军医大学“人才工程雏鹰计划”项目（KT2021HQ021）

Treatment of some genodermatoses

Jin Liang¹, Liu Ling²

¹Department of Dermatology, Air Force Medical Center, PLA, Beijing 100142, China; ²Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi′an 710032, China

Received:2022-01-04 Revised:2022-02-25 Published:2022-08-02
Contact: Liu Ling E-mail:vanilla@fmmu.edu.cn
Supported by:
"Young Eagle Program of Talent Project" of Air Force Military Medical University（KT2021HQ021）

摘要/Abstract

摘要： 【摘要】遗传性皮肤病是皮肤病中相对独立的体系，发病较早、临床表现复杂、累及系统多，目前治疗手段有限且疗效欠佳，患者生活质量受到较大影响。本文梳理总结部分遗传性皮肤病的前瞻性治疗方法和研究进展，包括传统药物的创新应用、生物制剂和小分子靶向药物、干细胞治疗和基因编辑，旨在为临床医生提供更多参考。

关键词: 皮肤疾病, 遗传性, 治疗, 生物制剂, 干细胞, 小分子靶向药, 基因编辑

Abstract: 【Abstract】 Genodermatoses are a relatively independent type of skin diseases, with early onset, complex clinical manifestations and multiple system involvement. Current treatments of genodermatoses are still limited with poor therapeutic effect, and the quality of life of patients is greatly affected. This review summarizes prospective treatment methods of some hereditary skin diseases and related research progress, including innovative application of traditional medicines, biologics and small-molecule targeted drugs, stem cell therapy and gene editing, aiming to provide more reference for clinicians.

Key words: Skin diseases, genetic, Therapy, Biological agents, Stem cells, Small molecular targeted drugs, Gene editing

晋亮刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022,55(8):735-739. doi:10.35541/cjd.20220001

Jin Liang, Liu Ling. Treatment of some genodermatoses[J]. Chinese Journal of Dermatology, 2022, 55(8): 735-739.doi:10.35541/cjd.20220001

参考文献 49

［1］	Lincoln V, Cogan J, Hou Y, et al. Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa［J］. Proc Natl Acad Sci U S A, 2018,115（28）:E6536⁃E6545. doi: 10.1073/pnas.18031 54115.
［2］	Hammersen J, Neuner A, Wild F, et al. Attenuation of severe generalized junctional epidermolysis bullosa by systemic treatment with gentamicin［J］. Dermatology, 2019,235（4）:315⁃322. doi: 10.1159/000499906.
［3］	Kwong A, Cogan J, Hou Y, et al. Gentamicin induces laminin 332 and improves wound healing in junctional epidermolysis bullosa patients with nonsense mutations［J］. Mol Ther, 2020,28（5）:1327⁃1338. doi: 10.1016/j.ymthe.2020.03.006.
［4］	Woodley DT, Cogan J, Hou Y, et al. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients［J］. J Clin Invest, 2017,127（8）:3028⁃3038. doi: 10.1172/JCI92707.
［5］	Vishwanath T, Agrawal S, Ghate S, et al. Intrabullous injection: a novel, painless technique of drug delivery in localized bullous dermatoses［J］. J Am Acad Dermatol, 2019,81（6）:e161⁃e163. doi: 10.1016/j.jaad.2019.06.039.
［6］	李越, 梁键莹, 程茹虹, 等. 庆大霉素软膏治疗无义突变引起的营养不良性大疱性表皮松解症的临床疗效观察［J］. 中国皮肤性病学杂志, 2020,34（6）:650⁃654. doi: 10.13735/j.cjdv. 1001⁃7089.201909131.
［7］	Wang J, Liu Y, Liu F, et al. Loss⁃of⁃function mutation in PMVK causes autosomal dominant disseminated superficial poro⁃keratosis［J］. Sci Rep, 2016,6:24226. doi: 10.1038/srep24226.
［8］	Zhang SQ, Jiang T, Li M, et al. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis［J］. Nat Genet, 2012,44（10）:1156⁃1160. doi: 10.1038/ng.2409.
［9］	Atzmony L, Khan HM, Lim YH, et al. Second⁃hit, postzygotic PMVK and MVD mutations in linear porokeratosis［J］. JAMA Dermatol, 2019,155（5）:548⁃555. doi: 10.1001/jamadermatol. 2019.0016.
［10］	Kubo A, Sasaki T, Suzuki H, et al. Clonal expansion of second⁃hit cells with somatic recombinations or C>T transitions form porokeratosis in MVD or MVK mutant heterozygotes［J］. J Invest Dermatol, 2019,139（12）:2458⁃2466.e9. doi: 10.1016/j.jid.2019. 05.020.
［11］	Paller AS, van Steensel MA, Rodriguez⁃Martín M, et al. Pathogenesis⁃based therapy reverses cutaneous abnormalities in an inherited disorder of distal cholesterol metabolism［J］. J Invest Dermatol, 2011,131（11）:2242⁃2248. doi: 10.1038/jid. 2011.189.
［12］	Atzmony L, Lim YH, Hamilton C, et al. Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis⁃directed therapy［J］. J Am Acad Dermatol, 2020,82（1）:123⁃131. doi: 10.1016/j.jaad.2019.08.043.
［13］	Tomsitz D, Biedermann T. Successful treatment of disseminated superficial actinic porokeratosis with topical 2% cholesterol/ 2% lovastatin cream: a case series with 7 patients［J］. J Eur Acad Dermatol Venereol, 2022,36（1）:e52⁃e54. doi: 10.1111/jdv.17619.
［14］	Byth LA, Byth J. Topical simvastatin⁃cholesterol for disseminated superficial actinic porokeratosis: an open⁃label, split⁃body clinical trial［J］. Australas J Dermatol, 2021,62（3）:310⁃313. doi: 10.1111/ajd.13601.
［15］	Shimada BK, Pomozi V, Zoll J, et al. ABCC6, pyrophosphate and ectopic calcification: therapeutic solutions［J］. Int J Mol Sci, 2021,22（9）doi: 10.3390/ijms22094555.
［16］	Yoo JY, Blum RR, Singer GK, et al. A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum［J］. J Am Acad Dermatol, 2011,65（2）:341⁃348. doi: 10.1016/j.jaad.2010.05.023.
［17］	LaRusso J, Jiang Q, Li Q, et al. Ectopic mineralization of connective tissue in Abcc6-/- mice: effects of dietary modifications and a phosphate binder⁃⁃a preliminary study［J］. Exp Dermatol, 2008,17（3）:203⁃207. doi: 10.1111/j.1600⁃0625. 2007.00645.x.
［18］	Dabisch⁃Ruthe M, Kuzaj P, Götting C, et al. Pyrophosphates as a major inhibitor of matrix calcification in Pseudoxanthoma elasticum［J］. J Dermatol Sci, 2014,75（2）:109⁃120. doi: 10. 1016/j.jdermsci.2014.04.015.
［19］	Li Q, Kingman J, Sundberg JP, et al. Etidronate prevents, but does not reverse, ectopic mineralization in a mouse model of pseudoxanthoma elasticum （Abcc6（-/-））［J］. Oncotarget, 2018,9（56）:30721⁃30730. doi: 10.18632/oncotarget.10738.
［20］	Kranenburg G, de Jong PA, Bartstra JW, et al. Etidronate for prevention of ectopic mineralization in patients with pseudoxanthoma elasticum［J］. J Am Coll Cardiol, 2018,71（10）:1117⁃1126. doi: 10.1016/j.jacc.2017.12.062.
［21］	Schantl AE, Verhulst A, Neven E, et al. Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers［J］. Nat Commun, 2020,11（1）:721. doi: 10. 1038/s41467⁃019⁃14091⁃4.
［22］	Omarjee L, Nitschke Y, Verschuere S, et al. Severe early⁃onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate［J］. Br J Dermatol, 2020,183（2）:367⁃372. doi: 10.1111/bjd.18632.
［23］	Fogel AL, Hill S, Teng JM. Advances in the therapeutic use of mammalian target of rapamycin （mTOR） inhibitors in dermatology［J］. J Am Acad Dermatol, 2015,72（5）:879⁃889. doi: 10.1016/j.jaad.2015.01.014.
［24］	Koenig MK, Bell CS, Hebert AA, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial［J］. JAMA Dermatol, 2018,154（7）:773⁃780. doi: 10.1001/jamadermatol.2018.0464.
［25］	Liu YX, Zhang J, Nie XL, et al. The effect of topical sirolimus on superficial Kaposiform haemangioendothelioma［J］. Australas J Dermatol, 2021,62（2）:e329⁃e331. doi: 10.1111/ajd.13499.
［26］	Lee GH, Lekwuttikarn R, Tafoya E, et al. Transcriptomic repositioning analysis identifies mTOR inhibitor as potential therapy for epidermolysis bullosa simplex［J］. J Invest Dermatol, 2022,142（2）:382⁃389. doi: 10.1016/j.jid.2021.07.170.
［27］	Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia［J］. Blood, 2005,105（7）:2640⁃2653. doi: 10.1182/blood⁃2004⁃08⁃3097.
［28］	Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery ⁃ past, present and future［J］. Nat Rev Drug Discov, 2014,13（8）:588⁃602. doi: 10.1038/nrd4366.
［29］	Bedard PL, Hyman DM, Davids MS, et al. Small molecules, big impact: 20 years of targeted therapy in oncology［J］. Lancet, 2020,395（10229）:1078⁃1088. doi: 10.1016/S0140⁃6736（20）30164⁃1.
［30］	Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors［J］. Oncologist, 2007,12（4）:426⁃437. doi: 10.1634/theoncologist.12⁃4⁃426.
［31］	Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma［J］. N Engl J Med, 2010,363（9）:809⁃819. doi: 10.1056/NEJMoa1002011.
［32］	Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal⁃cell carcinoma［J］. N Engl J Med, 2012,366（23）:2171⁃2179. doi: 10.1056/NEJMoa1113713.
［33］	Verstovsek S, Gotlib J, Mesa RA, et al. Long⁃term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT⁃I and ⁃II pooled analyses［J］. J Hematol Oncol, 2017,10（1）:156. doi: 10.1186/s13045⁃017⁃0527⁃7.
［34］	Attwood MM, Fabbro D, Sokolov AV, et al. Trends in kinase drug discovery: targets, indications and inhibitor design［J］. Nat Rev Drug Discov, 2021,20（11）:839⁃861. doi: 10.1038/s41573⁃021⁃00252⁃y.
［35］	Liddle J, Beneton V, Benson M, et al. A potent and selective kallikrein⁃5 inhibitor delivers high pharmacological activity in skin from patients with Netherton syndrome［J］. J Invest Dermatol, 2021,141（9）:2272⁃2279. doi: 10.1016/j.jid.2021.01. 029.
［36］	Murase C, Takeichi T, Taki T, et al. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome［J］. J Dermatol Sci, 2021,102（2）:126⁃129. doi: 10. 1016/j.jdermsci.2021.03.003.
［37］	Wang J, Yu L, Zhang S, et al. Successful treatment of Netherton syndrome with dupilumab: a case report and review of the literature［J］. J Dermatol, 2022,49（1）:165⁃167. doi: 10.1111/1346⁃8138.16253.
［38］	Steuer AB, Cohen DE. Treatment of Netherton syndrome with dupilumab［J］. JAMA Dermatol, 2020,156（3）:350⁃351. doi: 10.1001/jamadermatol.2019.4608.
［39］	Chello C, Sernicola A, Paolino G, et al. Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis［J］. An Bras Dermatol, 2021,96（5）:638⁃640. doi: 10.1016/j.abd.2020.10.006.
［40］	De Luca M, Aiuti A, Cossu G, et al. Advances in stem cell research and therapeutic development［J］. Nat Cell Biol, 2019,21（7）:801⁃811. doi: 10.1038/s41556⁃019⁃0344⁃z.
［41］	Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells［J］. Nature, 2017,551（7680）:327⁃332. doi: 10.1038/nature24487.
［42］	Abeona Therapeutics. VIITAL: phase III clinical trial of EB⁃101 for RDEB［EB/OL］.［2022⁃4⁃7］. https://www.debra.org/viital⁃phase⁃iii⁃clinical⁃trial⁃eb⁃101⁃rdeb.
［43］	Shi N, Yang Q, Zhang H, et al. Restoration of dystrophin expression in mice by suppressing a nonsense mutation through the incorporation of unnatural amino acids［J］. Nat Biomed Eng, 2022,6（2）:195⁃206. doi: 10.1038/s41551⁃021⁃00774⁃1.
［44］	Shinkuma S, Guo Z, Christiano AM. Site⁃specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa［J］. Proc Natl Acad Sci U S A, 2016,113（20）:5676⁃5681. doi: 10.1073/pnas.15120 28113.
［45］	Kocher T, Peking P, Klausegger A, et al. Cut and paste: efficient homology⁃directed repair of a dominant negative KRT14 mutation via CRISPR/Cas9 nickases［J］. Mol Ther, 2017,25（11）:2585⁃2598. doi: 10.1016/j.ymthe.2017.08.015.
［46］	Jacków J, Guo Z, Hansen C, et al. CRISPR/Cas9⁃based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells［J］. Proc Natl Acad Sci U S A, 2019,116（52）:26846⁃26852. doi: 10.1073/pnas.190708 1116.
［47］	Benati D, Miselli F, Cocchiarella F, et al. CRISPR/Cas9⁃mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient［J］. Mol Ther, 2018,26（11）:2592⁃2603. doi: 10.1016/j.ymthe.2018.07. 024.
［48］	Wu W, Lu Z, Li F, et al. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model［J］. Proc Natl Acad Sci U S A, 2017,114（7）:1660⁃1665. doi: 10.1073/pnas.1614775114.
［49］	Luan XR, Chen XL, Tang YX, et al. CRISPR/Cas9⁃mediated treatment ameliorates the phenotype of the epidermolytic palmoplantar keratoderma⁃like mouse［J］. Mol Ther Nucleic Acids, 2018,12:220⁃228. doi: 10.1016/j.omtn.2018.05.005.

[1]	闫娜刘燕李华军李洋谭宣丰杨怡晋亮. ACVRL1基因突变致合并主动脉窦瘤的遗传性出血性毛细血管扩张症1家系调查[J]. 中华皮肤科杂志, 2022, 55(8): 716-720.
[2]	魏瑾臧东杰曾三武蒋靖伦文辉. Dowling-Degos病1家系KRT5基因新突变分析[J]. 中华皮肤科杂志, 2022, 55(8): 703-705.
[3]	樊碧娆陈喜雪王明悦. [开放获取] 米诺环素单药或联合小剂量糖皮质激素治疗红斑型天疱疮15例和疱疹样天疱疮9例疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(8): 676-681.
[4]	曹淼崇杉胡新媛朱学骏王明悦. 副肿瘤性天疱疮患者原发肿瘤切除后皮肤黏膜感染及管理分析[J]. 中华皮肤科杂志, 2022, 55(8): 669-675.
[5]	王建波张帅邵依窦进法王晨张守民李振鲁. 遗传性对称性色素异常症2例ADAR基因突变分析及家系调查[J]. 中华皮肤科杂志, 2022, 55(8): 690-692.
[6]	刘娟, 陈志明杨勇. 先天性鱼鳞病样红皮病3家系PNPLA1基因突变分析[J]. 中华皮肤科杂志, 2022, 55(8): 685-689.
[7]	徐哲. 对遗传性皮肤病的一些思考[J]. 中华皮肤科杂志, 2022, 55(8): 651-652.
[8]	王媛李志量李锁荆可孙超梁桂熔张寒梅冯素英. 抗p200类天疱疮7例临床及免疫血清学特征分析[J]. 中华皮肤科杂志, 2022, 55(7): 557-561.
[9]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[10]	王玲艳潘靖苗钢常晓丹金秋子郭宁宁张佳钰. 对生物制剂治疗抵抗的银屑病患者皮损部位分析[J]. 中华皮肤科杂志, 2022, 55(7): 583-587.
[11]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.
[12]	吕莎王爽武寒飞张明瑞胡馨李福秋. 孢子丝菌病研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 629-632.
[13]	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470.
[14]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[15]	赵柳琦陈妍陈丹阳樊碧娆王瑞尚盼盼陈喜雪朱学骏王明悦. 【开放获取】度普利尤单抗治疗大疱性类天疱疮21例的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(6): 480-485.

部分遗传性皮肤病的治疗进展

Treatment of some genodermatoses

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 49

相关文章 15

Metrics

本文评价

推荐阅读 10